Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (August 2011)

22 slides from Zydus Lifesciences's investor presentation, August 2011

  1. Slide 1: Cadila Healthcare Ltd. Investor Presentation

    Cadila Healthcare Ltd. Investor Presentation August 2011 BSE : 532321 NSE : CADILAHC 1

  2. Slide 2: Our Vision

    Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline; Stepping beyond the billion, we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2

  3. Slide 3: A Snapshot

    A Snapshot  One of the largest company in the Indian formulations market  Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa and Middle East regions  Market leader in niche Indian consumer wellness market with strong brands  Win-win alliances with global pharmaceutical players

  4. Slide 4: Well integrated company and expanding globally

    Well integrated company and expanding globally Revenue break up (%) by segment (FY 10-11) APIs, 9% India ▲8% Formulations , 38% ▲19% Indian finished International dosage finished dosage formulations formulations India Exports Consumer, Formulations India 7% , 43%▲37% Others, 3%▲16% ▲25% High end API

  5. Slide 5: State of the art facilities and infrastructure (1/2)

    State of the art facilities and infrastructure (1/2) Finished Dosage Form, Finished Dosage Form, Baddi Finished Dosage Form, Sikkim Moraiya (USFDA Approved) (USFDA Approved) Finished Dosage Form, Goa Biologics Active Substances, Finished Dosage Form, Brazil Changodar API, Ankleshwar, API, Dabhasa On

  6. Slide 6: State of the art facilities and infrastructure (2/2)

    State of the art facilities and infrastructure (2/2) Facilities for complex products Vaccine Technology Center Topical Formulations Mfg., Transdermal Mfg., Ahmedabad Ahmedabad Moraiya Facilities for Partners Pantoprazole Intermediates Cytotoxic Injectible for Cytotoxic Injectible for Nycomed JV Hosp

  7. Slide 7: Financial highlights

    Financial highlights ▲26% ▲27% ▲26% ▲33% ▲40% ▲40% ▲57% ▲57% # Net Profit and EPS exclude Exceptional Items. 7

  8. Slide 8: One of the largest in Indian Pharma market with ~Rs 18 bn sales

    One of the largest in Indian Pharma market with ~ Rs 18 bn sales  Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory Therapeutic Area-wise Sales Break-up of (participated market segments) Branded Formulations (FY 10-11)  Continuous focus on increasing penetration in the

  9. Slide 9: International formulations: two-fold focus

    International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets (~32% of global sales) (~11% of global sales)  US - Zydus Pharmaceuticals USA Inc.  Brazil –  Europe • Branded - Quimica e Pharmaceutica Nikkho Do Brazil Ltda. • France - Zydus Fra

  10. Slide 10: Among the top 20 and one of the fastest growing generic companies in US

    Among the top 20 and one of the fastest growing generic companies in US  Ranked 12th amongst the top US generic companies based on scripts (Source : IMS)  Among the top three players in the market for ▲44% nine out of the top ten products marketed ▲69%  Focusing on delivery based, difficult to ma

  11. Slide 11: 9th largest generic company in France; among top 20 in Spain

    9th largest generic company in France; among top 20 generic companies in Spain Among top 10 in Euro 3 bn French generics market with over 2.5% market share  Launched >200 presentations (>90 molecules) in France so far  Focusing on expanding market coverage thru new product launches incl. Day 1 opp

  12. Slide 12: Strategies for Japan: World's 2nd largest pharma market

    Strategies for Japan : World’s 2nd largest pharma market  Generic market valued at >$ 3.5 bn, growing at over 10%, with low generic penetration of ~7% in value terms, 22% in volume terms (Source : IGPA)  Acquired Nippon Universal Pharma. Ltd. (now Zydus Pharma Japan - ZPJ), with a marketing set-up

  13. Slide 13: Strategies for $13bn Brazilian pharma market

    Strategies for $ 13bn Brazilian pharma market  Set up Zydus Healthcare Brazil Ltda. (100% Sales in Brazil (Rs. Mio.) subsidiary) to enter generics market in 2005-06 2,250 ▲24%  Filed 64 dossiers so far for generic and 1,628 1,818 branded products from India, of which 23 ▲12% have been approved. 

  14. Slide 14: Achievements in the fast growing emerging markets

    Achievements in the fast growing emerging markets  Operations in ~20 semi / non regulated emerging markets of Asia Pacific, Africa and Middle East regions  Focusing on rapidly growing markets of South Africa, Taiwan and Philippines  No.1 Indian company in Uganda and Sudan and amongst top 3 Indian

  15. Slide 15: Strong brand equity in consumer wellness segment in India

    Strong brand equity in highly potential consumer wellness segment in India  Zydus Wellness Ltd. – spearheading operations in Sales - Zydus Wellness (Rs. Mio.) consumer wellness segment 3,355 ▲25%  Strong presence in niche categories 2,675 1,947 ▲37%  India’s largest selling sugar substitute with

  16. Slide 16: Unlocking value through win-win alliances

    Unlocking value through win-win alliances  Zydus Nycomed JV – most successful contract manufacturing JV in India  State-of-the-art mfg. facility for Pantoprazole key intermediates  Commissioned the expanded facility to manufacture complex high-end APIs for Nycomed  Zydus Hospira - JV for oncolog

  17. Slide 17: Ongoing Investment in Newer Portfolios Worth over $180 bn

    Ongoing Investment in Newer Portfolios Worth over $ 180 bn Long term Novel discovery products Mid term from Zydus NME pipeline Biogenerics : 40 bn Near term Transdermal : 10 bn Vaccine : 22 bn Pulmonary : 20 bn Topical : 16 bn Transdermal : 10 bn Current Business Injectables : 17 bn Oncology : 55 bn

  18. Slide 18: Diversified R&D investments spread across three key areas

    Diversified R&D investments spread across three key areas High API process research NME, Biologics & Vaccines • Located at Dabhasa • Located near Ahmedabad • 150+ scientists • 450+ scientists Returns • Focus on chemical process development • Focus on NME research, • Work on complex and biosimilars,

  19. Slide 19: Dedicated facility for NME research: Zydus Research Centre

    Dedicated facility for NME research : Zydus Research Centre  Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation  Facility for target identification to pre- clinical research / early clinical development  Signed a new drug discovery and development pact with Eli Lilly and Co., focused o

  20. Slide 20: Biosimilars and Vaccines – The Next Big Opportunity

    Biosimilars and Vaccines – The Next Big Opportunity Biosimilars :  Strong pipeline: 17 biosimilars and 2 novel products  Strong IP position either through own patent or non-infringing processes  100+ experienced scientists dedicated to Biosimilars programme  End to end product development and mf

  21. Slide 21: Key Financial Numbers – FY 2010-11

    Key Financial Numbers – FY 2010-11 Rs. Mio. Growth Consolidated Profitability 2010-11 2009-10 y-y% Total Gross Sales 45,211 36,142 25.1% Total Income from Operations 46,302 36,868 25.6% EBIDT 10,262 8,086 26.9% EBIDT % to Total Income 22.2% 21.9% Net Profit # 7,110 5,092 39.6% Net Profit % to Total

  22. Slide 22: Safe Harbour Statement

    Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims a

Cadila Healthcare — Investor Presentation (August 2011) on 6ix